

Financial Results for the Fiscal Year Ended March 31, 2017 (FY2016) and Guidance for the Fiscal Year Ending March 31, 2018 (FY2017)

Terumo Corporation

Managing Executive Officer,

Investor Relations, Corporate Communication Dept.

Kazuaki Kitabatake

May 10, 2017

Achieved Growth in Sales and Profit w/ FXN, and Recorded Highest-ever Net Income

				(billion yen)
	FY2015	FY2016	YoY%	YoY% (Excl. FX)
Net Sales	525.0	514.2	-2%	+6%
Gross Profit	282.9 (53.9%)*	278.0 (54.1%) [*]	-2%	+8%
SG&A expenses	168.1 (32.0%)	167.7 (32.6%)	-0%	+9%
R&D Expenses	33.1 (6.3%)	33.7 (6.6%)	+2%	+8%
Operating Income	81.7 (15.6%)	76.6 (14.9%)	-6%	+7%
(Excl. Amortization)	101.9 (19.4%)	97.3 (18.9%)	-5%	+8%
Ordinary Income	73.1 (13.9%)	68.6 (13.3%)	-6%	
Net Income	50.7 (9.7%)	54.2 (10.5%)	+7%	
Average Exchange Rate –	USD 120 yen EUR 133 yen	108 yen 119 yen		

Sales: Overseas continuous double digit growth in Cardiac and Vascular Company drove overall growth

Operating income: Improved gross margin due to expansion of highly profitable products in TIS, production volume increase in general hospital products, and reduced cost for quality system improvement

• Ordinary income: Decrease in posted FX loss on YoY (FY2015: 7.5 BJPY \rightarrow FY2016: 4.1BJPY)

Net income: Realized extraordinary loss due to termination of contract for co-development w/ French venture company. Gain from sales of Olympus's stocks

*Transferred some SG&A expenses for the independent manufacturing subsidiaries into COGS (2.0BJPY)



FY2016 Comparison between Guidance and Results

(billion yen)	FY2016 Guidance as of Feb 9 th	Results	Difference	•
Net Sales	510.0	514.2	+4.2	
Operating Income (%)	71.0 (13.9%)	76.6 (14.9%)	+5.6	I
Ordinary Income	62.0	68.6	+6.6	•
Net Income	47.5	54.2	+6.7	•
	USD 107 yen EUR 118 yen	108 yen 119 yen		

<Operating Income> Achieved sales above the forecast in access and neurovascular products +2.0Steady sales for acquired businesses +1.0Delay of realization for SG&A, etc. (Cardiac and Vascular company) +1.0R&D: Slight delay for clinical trial, receipt of R&D fee from partner companies +1.5<Ordinary Income> Less FX losses than expected, delay in realization of temporary cost for financing

+1.0

(billion yen)

<Net Income>

Gain from sales of Olympus's stocks, etc. +1.5




Extraordinary Gains & Losses, Income Taxes

Extraordinary Gains & Losses, income faxes						
	FY2015	FY2016				
Operating Income	81.7	76.6	YoY%: -6%			
Non-operating Income and loss	-8.6	-8.0	FX1H2HQ4YTDFY15-2.4-5.1-7.5FY16-6.6+2.5-4.1			
Ordinary Income	73.1	68.6	YoY%: -6%			
Extraordinary Gains & Losses	+3.8	+6.4	FY15 Sale of land in Hatagaya FY16 Termination of co-development w/ AR Gain from sale of equity	+4.4 T -7.0 +15.7		
Income before Income Tax	76.9	75.0	YoY%: -3%			
Income Taxes Total Tax Rate (%)	-26.2 34%	-20.8 28%	Tax effect due to past loss of valuation Olympus's stocks Terumo owns	for		
Net Income	50.7	54.2	YoY%: +7%			



Operating Income Variance Analysis



FY2015

FY2016 excl. FX and acquisitionrelated cost





FX Impact on Operating Income in FY2016

	FY15	Original FY	16 Guidance	Results in FY16		
Currencies	Rate (Yen)	Rate (yen)	Impact (billion yen)	Rate (yen)	Impact (billion yen)	
USD	120	110	1.9	108	2.7	
EUR	133	125	-2.3	119	-5.2	
CNY	19	17	-1.5	16	-2.3	
Others (Asia, L. America etc.)			-6.6		-6.1	
Total			-8.5		-10.9	



Net Sales by Region

FY16 FY15

			FY15					
Net Sales	Year-on-Year Sales Comparison							
100% = 514.2BJPY	billion yen	YoY%	Comments					
36% Japan	187.0 187.2	() FXN -0%	Access devices in TIS and neurovascular as well as infusion system and businesses in Blood Management Company drove overall growth. Reimbursement price cut. Ended YoY positive impact from sales of new coronary therapeutic devices launched in FY15 Closure device added further good momentum in continuous high growth for TIS, neurovascular, and					
Europe	95.0 101.8	-7% (+5%)	vascular graft (+9%). Large expansion of B2B for Pharma (22%). Downsizing low profitable accounts for general hospital products					
19% Americas	139.7 143.5	-3% (+8%)	Closure device accelerated the overall high growth in Cardiac and Vascular Company (+14%) Price decline for blood center products in Blood					
27% China	34.5 33.2	(+8%) +4% (+20%)	Management Company Achieved high growth in sales for all businesses in Cardiac and Vascular Company (+24%). Continuous double digit growth in General Hospital					
7%Asia and11%Others	57.9 59.3	-2% (+8%)	Company (+17%) General Hospital Company maintained good momentum mainly in IV catheter needles. Cardiac and Vascular Company achieved continuous double					
TERUMO		. ,	digit growth driven by TIS (+15%) 7/30					

Net Sales by Business Segment

FY16

					FY15				
Net Sales		es	Year-on-Year Sales Comparison						
100	0% = 514.	2BJPY	billion yen	YoY%	Comments				
				() FXN					
	51%	Cardiac and Vascular	261.5 258.6	+1% (+11%)	Despite the negative impact of reimbursement price cut, overseas TIS and neurovascular along with acquired closure device led overall double digit growth in the company				
	31%	General Hospital	157.9 161.4	-2% (+0%)	Growth mainly for infusion system and IV catheters offset the impact of downsizing low profitable accounts in EU and Latin Americas in general hospital products. Double digit growth in global D&D for overseas pharmaceutical companies alleviated the impact of reimbursement				
	18%	Blood Manage- ment	94.5 105.0	-10% (+0%)	price cut in D&D Continuous growth for businesses in emerging countries and apheresis system offset the impact of price decline for blood center product in US				



Cardiac and Vascular : Achieved Double Digit Growth Both in Sales and Profit

(billion yen)

				/ /	Jillon yen)
	FY2015	FY2016	YoY%	Major Topics	Impact
	258.6	261.5	() FXN	Negative Impact of FX	-25.5
Sales			+1% (+11%)	JPN: Reimbursement price cut. Annualized positive impact from the launch of new coronary therapeutic device in FY15. Double digit growth in neurovascular (+16%)	-0.6
				Overseas: All businesses showed positive growth. TIS and neurovascular achieved a double digit growth (+16%).	+22.7
				Increase in sales owing to acquisition	+6.3
Business Profit	63.4 (25%)	65.0	+3% (+22%)	Highly profitable products in TIS such as acce and coronary therapeutic devices drove over Impact of Misago recall (-2.0)	
	(25%)	(25%)			



General Hospital : Steady Progress in Profitability Improvement

(billion yen)

	FY2015	FY2016	YoY%	Major Topics	Impact
	161.4	157.9	() FXN -2%	Negative Impact of FX JPN: Infusion system maily drove overall growth in general hospital products Ended distribution of contrast agents	-4.0 +1.2 - 1.3
Sales			(+0%)	Overseas: Downsizing low profitable account in EU and Latin Americas Achieved high growth in B2B for pharmaceutical companies in EU IV catheter needles mainly drove an overall growth in China and other regions of Asia	ts - 1.5 + 0.8 + 1.1
Business Profit	22.6 (14%)	23.8 (15%)	+5% (+7%)	Increase in pension cost due to the lowering rate. Continuous cost reduction mainly in general products FY15: 13.9% → FY16: 15.0%	



Blood Management : Annualized Impact of Price Decline in US

(billion yen)

					(
	FY2015	FY2016	YoY%	Major Topics	Impact
			()FXN	Negative Impact of FX	-10.6
	105.0			Price declines for blood center products mainly in US	- 2.0
Sales	105.0	94.5	-10% (+0%)	Negative impact from stagnant macro economy in Russia and the Middle East countries	- 0.6
				Sales expansion in apheresis system	+ 1.8
				Blood center business in emerging countries continuously grew	+ 1.2
	16.9	13.6		Decrease in G/P due to price declines for b	blood center
Busine	ss	13.0	-20% (-6%)	products along with increase in R&D investment and	
Profit				start-up cost for new factory in Vietnam.	
	(16%)	(14%)		Decrease in profit due to FX, yet achieved	more profit

than the guidance level w/ FXN.

Major Topics in FY2016

Announced adoption of IFRS (Nov)

Announced 5-Year Mid- to Long-term Growth Strategy (Dec)

Corporate

Share buyback of 44.2 BJPY (Feb)

Selected as "the Health and Productivity Stock Selection" for three consecutive years (Feb)

"AdSpray" obtained regulatory approval for the first time in spray type adhesion barrier in Japan (Jun)

FDA lifted all shipping restrictions at TCVS (Jun)

Business

Strengthened product portfolio in Cardiac and Vascular Company through M&As

- Acquisition of US-based Sequent Medical for new neurovascular aneurysm embolization device (Jun)
- Acquisition of vascular closure devices, etc.
 from St. Jude Medical and Abbott Laboratory (Dec)
 - Acquisition of US-based Bolton Medical for TAA and AAA stent grafts (Jan)



New Products Pipeline in FY2016

Category	Products		Region	Launch	Category	Products		Region	Launch
Coronary	DES (Ultimaster)	◎ ★	France	Launched	cv	Disposable Centrifugal Pump (for PCPS)		Asia	Launched
	DES (Ultimaster) 4.0mm	◎★	JP	Launched	Regenerative Medicine	HeartSheet	*	JP	Launched
Imaging	IVUS	◎★	JP	Launched		Intradermal Injection Device	*	JP	To be launched in FY17
	PTA Balloon (Below the knee, RX/OTW)		JP∙US∙EU	Launched in JP & US	D&D	Adhesion barrier	*	JP	Launched
Peripheral	PTA Balloon (Below & above the knee, RX/OTW)		JP∙US∙EU	Launched in JP & US	DM	Blood glucose meter (MEDISAFE Fit Smile)		China	To be launched in FY17
	PTA Balloon (Above the knee, RX/OTW)		JP∙US∙EU	Launched	Blood Management	Automated blood component processing system	*	JP	Launched
Neuro	Distal protection device		EU	To be launched in FY17	60		9	TT - TT	IVUS
Oncology	Radioembolization beads (Quirem)	*	EU	To be launched in FY17	3	Adhesion barrier	7		"AltaView"
	n with large contribution		-	fit	DES "Ultimaster				~

JP, France

 \star Item with highly innovative technology

TERUMO

JP

			(billion yen)	Reference
	FY16 Results	FY17 Guidance	ΥοΥ%	IFRS Basis FY17 Guidance
Net Sales	514.2	575.0	+12%	575.0
Operating Income (%)	76.6 (14.9%)	82.0 (14.3%)	+7%	95.0 (16.5%)
Ordinary Income	68.6	79.5	+16%	
Net Income	54.2	53.0	-2%	68.0
Average Exchange Rate	USD 108 yen EUR 119 yen	110 yen 120 yen		

In FY17 guidance, figures related to acquisition is tentative since PPA is still in process.




FY17 Guidance (excl. Impacts of FX and M&As)

(billion yen)

	FY16 Result Excl. M&As	FY17 Guidance w/ FXN Excl. M&As	ΥοΥ%	FX Impact	M&As Impact	FY17 Guidance
Net Sales	507.8	536.5	+6%	+6.0	+32.5	575.0
Operating Income (%)	81.1 (16.0%)	87.5 (16.3%)	+8%	+1.5	-7.0	82.0 (14.3%)
Ordinary Income	73.2	85.5	+17%	+1.5	-7.5	79.5
Net Income	58.7	56.5	-4%	+1.0	-4.5	53.0
Average Exchange Rate	USD 108 yen EUR 119 yen					110 yen 120 yen




FY2017 Annual Guidance





FY2017 Guidance : Increase of Sales and Profit in All Three Companies



* W/ FXN, Incl. impact of M&A



New Products Pipeline in FY2017

Category	Products		Region	Category	Products		Region
Coronary	PTCA balloon		US	<i></i>	Heart lung machine (Re-launch)	O	Global
	Stent (TRI)	*	JP, US & EU	CV	Next generation of oxygenator	O	Global
	PTA balloon (TRI)	*	JP, US & EU	General	Vertical infusion pump		JP
Peripheral	PTA guiding sheath (TRI)	*	JP, US & EU	Hospital Products	Needleless infusion system for Anti-cancer drugs		JP
	Drug coated balloon	◎★	EU	DM	Insulin patch pump	*	JP
	Embolization coil	Ø	EU	Blood Management	New software for automated to blood collection system		Global
Norma	Distal protection device		EU			10p	
Neuro	Hydrogel coil 3D		JP, US & EU			M	ANGE
Oncology	Radioembolization beads (Quirem)	*	EU			TERUMO	
	ith large contribution to sales	•	fit	Drug Coated Ba "Kanshas"	lloon Heart Lung Machine Re-launch	Insulin F	Patch Pump

EU

 \star Item with highly innovative technology

TERUMO

JP

Global

Reference



(billion yen)

Business	Business		Outside of Japan					
Segment	Segment Japan	Subtotal	Europe	Americas	China	Asia	G. Total	
Cardiac and Vascular	51.0 (-1%)	210.6 (+14%)	64.7 (+9%)	92.0 (+14%)	28.2 (+24%)	25.6 (+15%)	261.5 (+11%)	
Out of C&V Interventional Systems*	38.8 (-2%)	170.1 (+16%)	53.1 (+11%)	69.1 (+17%)	26.8 (+23%)	21.2 (+19%)	208.9 (+13%)	
General Hospital	123.8 (-0%)	34.1 (+2%)	7.8 (-7%)	7.8 (+5%)	1.9 (+17%)	16.6 (+5%)	157.9 (+0%)	
Blood Manage- ment	12.0 (+5%)	82.5 (-1%)	22.4 (-1%)	39.9 (-2%)	4.4 (+4%)	15.8 (+2%)	94.5 (+0%)	
G. Total	187.0 (-0%)	327.2 (+9%)	95.0 (+5%)	139.7 (+8%)	34.5 (+20%)	57.9 (+8%)	514.2 (+6%)	

*Including Neurovascular business

rerumo

(YoY%): Excluding foreign exchange

20/30

					(billion yen)
	FY2015	FY2016	YoY	YoY%	YoY% (Excl. FX)
Salaries & Wages	75.1	74.6	- 0.5	-1%	+8%
Sales Promotion	17.2	15.6	-1.6	-9%	-2%
Logistical Costs	11.0	11.2	+0.2	+2%	+6%
Depreciation & Amortization	27.4	27.5	+0.1	+0%	+10%
Others	37.4	38.8	+1.4	+4%	+11%
SG&A Expenses Total	168.1 (32.0%)	167.7 (32.6%)	-0.4	-0%	+9%
R&D Expenses	33.1 (6.3%)	33.7 (6.6%)	+0.6	+2%	+8%
Operating Expenses Total	201.2 (38.3%)	201.4 (39.2%)	+0.2	+0%	+8%




Quarterly Results

					(billion yen)
	FY15 Q4 (Jan-Mar)	FY16 Q1 (Apr-Jun)	Q2 (Jul-Sep)	Q3 (Oct-Dec)	Q4 (Jan-Mar)
Net Sales	129.0	124.5	120.6	129.3	139.8
Gross Profit	69.7 (54.0%)	69.2 (55.6%)	65.8 (54.6%)	68.7 (53.2%)	74.3 (53.2%)
SG&A Expenses	42.2 (32.7%)	39.7 (31.9%)	39.6 (32.9%)	41.0 (31.7%)	47.4 (34.0%)
R&D Expenses	9.9 (7.7%)	8.1 (6.5%)	8.2 (6.8%)	8.2 (6.4%)	9.2 (6.6%)
Operating Income	17.6 (13.6%)	21.4 (17.2%)	18.0 (14.9%)	19.5 (15.1%)	17.7 (12.6%)
(Excl. Amortization)	22.5 (17.4%)	25.9 (20.8%)	22.6 (18.8%)	24.5 (19.0%)	24.2 (17.4%)
Average USD	115 yen	108 yen	102 yen	109 yen	114 yen
Exchange Rate EUR	127 yen	122 yen	114 yen	118 yen	121 yen

*Transferred SG&A expenses for the independent manufacturing Subsidiaries into COGS



CAPEX and R&D Expenses



FY2014


FY2015

FY2016

Expenses

FY2013

ERUMO



41.0


FY2017 Guidance

Expand investment in production capacity and space as well as IT infrastructure in FY17

- Amortization of intangibles and goodwill in FY17 are projected to increase due to M&As in FY16
- Further promote USbased R&D activities for TIS and neurovascular

23/30

Cash Flow





Financing Capital for M&As by Self-financing and Low-Interest Debt

- Make use of low interest rate while considering financial soundness
- Financing since the introduction of minus interest rate policy
 - Jan, 2017 Syndicate loans(*)
 Apr, 2017 Syndicate loans(*)
 Apr, 2017 Straight bonds

30.0 BJPY 120.0 BJPY 20.0 BJPY

✓ Loan term 3-10 yrs (Average: 7yrs)

(*)A part of financing comes from JBIC

- Despite increase in interest bearing debt, interest expenses decreases.
 - > FY15 1.4BJPY → FY16 1.2BJPY → FY17 1.0 BJPY



(billion yen)

	USD		EUR	CNY
	Excl. Amortization	Incl. Amortization		
Net Sales	1.6	1.6	0.8	1.8
Operating Income	0.0	-0.2	0.5	0.9

<Reference> Impact of +/-10% fluctuation

	North	Latin	EMEA		Asia	
	America	America	EUR	Others	CNY	Others
Operating Income	-1.8	0.8	5.6	1.0	1.4	3.3



27/30

FY17 Guidance: Adoption of International Financial Reporting Standards (IFRS)

- Adopting International Financial Reporting Standards (IFRS) from the yearend financial announcement for FY2017
- Schedule for disclosure

FY17 Q1-Q3

: Japanese GAAP

FY17 year-end financial announcement : IFRS

(billion yen)	Japanese GAAP	IFRS	Impact
Net Sales	575.0	575.0	-
Operating Income (%)	82.0 (14.3%)	95.0 (16.5%)	+13.0
Adjusted Operating Income (%)	110.5 (19.2%)	110.0 (19.1%)	-0.5
Net Income	53.0	68.0	+15.0

<u>Major Impact</u>


- Non-amortization of goodwill
- Transferring items in non-operating gains and losses into operating income in P/L

Adjusted Operating Income

Business profit, that is, O/P for IFRS basis w/o cost of M&A, amortization of intangibles, and temporary cost (≒ existing "Operating Income excl. Amortization")




Dividends and EPS





Achieved 10% range





Terumo Corporation

Corporate Communication (IR) Dept.

E-mail: kouhou_terumo01@terumo.co.jp

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

The market share information in this presentation is partly derived from our own independent research.

